National Centre for Pharmacoeconomics

National Centre for
Pharmacoeconomics

NCPE Ireland

Victoza®  is indicated for treatment of adults with type 2 diabetes mellitus.

 

NCPE Assessment Process Complete
Rapid review received 01/09/2009
Rapid review completed 07/10/2009
Rapid Review outcome Full pharmacoeconomic evaluation not recommended

 

 The HSE has now requested a full HTA for this product 26 October 2016
Full pharmacoeconomic assessment commissioned by HSE 26/10/2016
Pre-submission consultation with Applicant 21/02/2017
Submission received from Applicant 29/08/2017
Preliminary review sent to Applicant 17/08/2018
NCPE assessment re-commenced 30/10/2018
Factual accuracy sent to Applicant 07/02/2019
NCPE assessment re-commenced 18/02/2019
NCPE assessment completed 07/03/2019
NCPE assessment outcome The NCPE recommends that liraglutide (Victoza®) not be considered for reimbursement unless cost-effectiveness can be improved relative to existing treatments.  This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.

Summary